Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study

Histopathology

Volumn 60, Issue 6, 2012, Pages 999-1003

  Scheipl, Susanne ^a   Froehlich, Elke V ^a   Leithner, Andreas ^a   Beham, Alfred ^a   Quehenberger, Franz ^a   Mokry, Michael ^a   Stammberger, Heinz ^a   Varga, Peter P ^b   Lazáry, Aron ^b   Windhager, Reinhard ^c   Gattenloehner, Stefan ^d   Liegl, Bernadette ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Brachyury; Chordoma; IGF 1; IGF 1 signalling; IGF 1R; IGF 2; Immunohistochemistry; Survival; Targeted therapies

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHORDOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SKELETON; TUMOR CELL; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHORDOMA; FEMALE; GERMANY; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, IGF TYPE 1; RETROSPECTIVE STUDIES; SPINAL NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84860269386     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04186.x     Document Type: Article

References (18)

1. Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. Curr. Opin. Oncol. 2007; 19; 367-370.
2. Muro K, Das S, Raizer JJ. Chordomas of the craniospinal axis: multimodality surgical, radiation and medical management strategies. Exp. Rev. Neurother. 2007; 7; 1295-1312.
3. Salisbury AJ, Macaulay VM. Development of molecular agents for IGF receptor targeting. Horm. Metab. Res. 2003; 35; 843-849.
4. Mirra JM, Della Rocca C, Nelson SD, Mertens F. Chordoma. In Fletcher CDM, Unni KK, Mertens F eds. World Health Organization classification of tumours. pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press, 2002; 316-317.
5. Sciubba DM, Chi JH, Rhines LD, Gokaslan ZL. Chordoma of the spinal column. Neurosurg. Clin. N. Am. 2008; 19; 5-15.
6. Papagelopoulos PJ, Mavrogenis AF, Galanis EC et al. Chordoma of the spine: clinicopathological features, diagnosis, and treatment. Orthopedics 2004; 27; 1256-1263.
7. Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr. Relat. Cancer 2006; 13; S33-S43.
8. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin. Cancer Res. 2008; 14; 6364-6370.
9. Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT. The insulin-like growth factor system and sarcomas. J. Pathol. 2009; 217; 469-482.
10. Avnet S, Sciacca L, Salerno M et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res. 2009; 69; 2443-2452.
11. Duan Z, Choy E, Harmon D et al. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol. Cancer Ther. 2009; 8; 2122-2130.
12. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr. Opin. Oncol. 2008; 20; 419-427.
13. Mitsuhashi T WM, Sasano H, Ono M. The expression of insulin-like growth factor-1 (IGF-1), IGF-1 receptor and transforming growth factor-beta in chordoma. Mod. Pathol. 2006; 19(Suppl. 3); 6.
14. Mitsuhashi T AH, Hasegawa T. Insulin-like growth factor (IGF)-I and IGF-I receptor (IGF-IR) are consistently expressed in the most of chordomas. Mod. Pathol. 2008; 21(Suppl. 1); 15A-16A.
15. Sommer J, Itani DM, Homlar KC et al. Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma. J. Pathol. 2010; 220; 608-617.
16. Shang Y, Mao Y, Batson J et al. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Mol. Cancer Ther. 2008; 7; 2599-2608.
17. Presneau N, Shalaby A, Idowu B et al. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br. J. Cancer 2009; 100; 1406-1414.
18. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ. The insulin-like growth factor-1 receptor-targeting antibody, CP-751, 871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res. 2009; 69; 7662-7671.